Intercell's clinical data on Japanese Encephalitis vaccine published in The Lancet

» Intercell´s (ICLL) Phase III clinical trial results on its investigational Japanese Encephalitis vaccine have been published in the renowned medical journal "The Lancet"

» The article is the first publication describing the full clinical data to date on Intercell´s vaccine against Japanese Encephalitis

» The publication details significant safety and immunogenicity results on the ICLL vaccine, which represents an innovative approach against a disease with a high degree of unmet medical need

(Vienna, 3. 12. 2007) Intercell (VSE: ICLL) is pleased to announce the acceptance of a scientific article about its investigational Japanese Encephalitis vaccine by the internationally-renowned scientific and medical journal "The Lancet".

With over 3 billion people living in endemic areas, Japanese Encephalitis, a mosquito-borne flaviviral infection, is the leading cause of childhood encephalitis and viral encephalitis in Asia. Japanese Encephalitis represents a clear threat to travellers and military personnel from industrialized countries visiting endemic areas. The disease is usually severe, resulting in residual neuropsychiatric sequelae in up to 50% of cases and a fatal outcome in about 25% of all cases. No treatment is currently available, only vaccination effectively prevents the disease.
Intercell´s innovative investigational vaccine, which is planned to enter global markets in 2008,
is a purified, inactivated product for active immunization against viral infections of Japanese Encephalitis.

In a recently concluded Phase III non-inferiority trial, Intercell’s investigational Japanese Encephalitis vaccine demonstrated

» Immunogenicity against Japanese Encephalitis comparable to that of the U.S. licensed product, JE-VAX®

» An overall clinical safety profile similar to placebo combined with an excellent local tolerability profile Intercell’s innovative investigational vaccine, which is manufactured in the company’s proprietary manufacturing facility in Scotland, is prepared using tissue culture rather than live organisms and does not contain stabilizers such as gelatin or preservatives in its formulation.

The article published in "The Lancet" reports of the detailed findings in a multicenter,
multinational, observer-blinded randomized controlled Phase III non-inferiority study. The paper was written under the lead of Intercell´s Vice President of Clinical Development &
Medical Officer, Dr. Erich Tauber, in cooperation with scientists from the Medical University of Vienna, Austria and University of Washington, Seattle, USA as well as the Medical University Innsbruck, Austria.

"This publication on our vaccine means that Intercell’s approach and the data of our study have been peer-reviewed by highly-ranked independent scientific and medical experts, who came to the conclusion that our innovative vaccine, if approved, will meet a major medical need," stated Alexander von Gabain, Chief Scientific Officer of Intercell AG. He added: "It is a valuable appreciation of our scientific work that our data has been published in The Lancet,
which is one of the world’s leading medical journals."

"The Lancet", which first appeared in the year 1823, is an independent and authoritative voice in global medicine that seeks to publish high-quality clinical trials that will alter medical practice. "The Lancet" delivers in-depth knowledge in key medical disciplines.

About Intercell AG:

Intercell AG is a growing biotechnology company which focuses on the design and development of novel vaccines for the prevention and treatment of infectious diseases with substantial unmet medical need. The Company develops antigens and adjuvants which are derived from its proprietary technology platforms, and has in-house GMP manufacturing capability. Based on these technologies, Intercell has strategic partnerships with a number of global pharmaceutical companies, including Novartis, Merck & Co., Inc., Wyeth, sanofi pasteur, Kirin, and the Statens Serum Institut.

The Company’s leading product, a prophylactic vaccine against Japanese Encephalitis Virus,
successfully concluded pivotal Phase III clinical trials in 2006. The regulatory process toward a Biological License Application (BLA) to the U.S. Food and Drug Administration (FDA) has been initiated. The broad development pipeline includes a Pseudomonas vaccine in Phase II, a therapeutic vaccine for Hepatitis C Virus in Phase II, partnered vaccines for Tuberculosis and S. aureus which are in Phase I, and five products focused on infectious diseases in preclinical development.

Intercell is listed on the Vienna stock exchange under the symbol "ICLL".

For more information please visit:

Contact Intercell AG:
Intercell AG
Lucia Malfent Head of Corporate Communications Campus Vienna Biocenter 2, A-1030 Vienna P: +43-1-20620-303 Mail to: lmalfent(at)

This communication expressly or implicitly contains certain forward-looking statements concerning Intercell AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors that could cause the actual results, financial condition, performance or achievements of Intercell AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Intercell AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

The sender takes full responsibility for the content of this news item. Content may include forward-looking statements which, at the time they were made, were based on expectations of future events. Readers are cautioned not to rely on these forward-looking statements.

As a life sciences organization based in Vienna, would you like us to promote your news and events? If so, please send your contributions to news(at)